Kosin Medical Journal (고신대학교 의과대학 학술지)

Kosin University College of Medicine (고신대학교 의과대학)
권호 표지
DOI QR코드

DOI QR Code

Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor

  • Nho, In-Young (Department of Internal Medicine, Gwangmyeong Sungae Hospital) ;
  • Kim, Hae-Sung (Department of Internal Medicine, Sungae Hospital) ;
  • Kang, Nam-Kyu (Department of Internal Medicine, Gwangmyeong Sungae Hospital) ;
  • Lee, Myung-Won (Department of Internal Medicine, Gwangmyeong Sungae Hospital) ;
  • Kim, Soo-Kyung (Department of Internal Medicine, CHA Bundang Medical Center, CHA university) ;
  • Park, Seok-O (Department of Internal Medicine, Gwangmyeong Sungae Hospital)
  • Received : 2016.05.31
  • Accepted : 2016.09.21
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) are proposed as a novel approach for the management of type 2 diabetes mellitus. SGLT2 cotransporters are responsible for reabsorption of 90 % of the glucose filtered by the kidney. The glucuretic effect resulting from SGLT2 inhibition contributes to reduce hyperglycaemia and also assists weight loss and blood pressure reduction. In this study, we presented the case of a 59-year-old male who developed hyperosmolar hyperglycemic state (HHS), possibly caused by a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a novel class of antihyperglycemic agents. This case highlights that HHS can develop in patients with diabetes treated with SGLT2 inhibitors.

Keywords

References

  1. Bakris G, Fonseca V, Sharma K, Wright E. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7. https://doi.org/10.1038/ki.2009.87
  2. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42. https://doi.org/10.1210/jc.2009-0473
  3. Kim WJ, Kim SS. The side effects of sodium glucose cotransporter 2 (SGLT2) inhibitor. J Korean Diabetes 2014;15:158-62 https://doi.org/10.4093/jkd.2014.15.3.158
  4. FDA safety alert. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 15 May 2015.
  5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patientcentered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79. https://doi.org/10.2337/dc12-0413
  6. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ , Kreisberg RA , Malone JI, et al. Management of hyperglycemic crisis in patients with diabetes. Diabetes Care 2001;24:131-53. https://doi.org/10.2337/diacare.24.1.131
  7. Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006;29:2739-48. https://doi.org/10.2337/dc06-9916
  8. Ennis ED, Stahl EJVB, Kreisberg RA. The hyperosmolar hyperglycemic syndrome Diabetes Rev 1994;2:115-26.
  9. Delaney MF, Zisman A, Kettyle WM. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am 2000;29:683-705. https://doi.org/10.1016/S0889-8529(05)70159-6
  10. Suzuki M, Takeda M, Kito A, Fukazawa M, Yata T, Yamamoto, et al. Tofogliflozin, a sodium/ glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes 2014 7;4:e125.
  11. Hamamoto H, Noda M. Body Weight Gain and Hyperphagia After Administration of SGLT-2 Inhibitor: A Case Report. Am J Case Rep 2015;16:863-7. https://doi.org/10.12659/AJCR.896233
  12. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodiumglucose cotransporter 2 inhibition. Diabetes Care 2015;38:1730-5. https://doi.org/10.2337/dc15-0355